ZLAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ZLAB is not a good buy right now. Price action and momentum are decisively bearish (breakdown below near-term support with a worsening MACD), insiders are aggressively selling, and there are no near-term news catalysts to interrupt the downtrend. Even with some bullish skew in options positioning, the tape is weak enough that an impatient buyer is more likely to get a worse entry soon than a quick rebound.
Trend/momentum: Bearish. The moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), confirming a sustained downtrend. MACD histogram (-0.138) is below zero and expanding negatively, signaling accelerating downside momentum. RSI(6) at ~21 is oversold, which can spark short bounces, but in strong downtrends oversold conditions can persist. Key levels: The stock closed at 16.56, below S1 (16.831), indicating a support breakdown. Next support is S2 at 16.207; if that fails, downside can extend quickly. Overhead resistance/pivot area is 17.839, then 18.847.
Intellectia Proprietary Trading Signals
Analyst support: UBS initiated at Buy with a $35 target (large upside vs current price), which can help sentiment over time.
Revenue growth: 2025/Q3 revenue rose +13.52% YoY, indicating top-line progress.
Oversold setup: Very low short-term RSI can produce sharp mean-reversion bounces (tactical only).
Clear technical breakdown: Price below S1 with bearish MA stack and worsening MACD increases probability of continued decline.
Insider selling: Insiders are selling, with selling amount up ~2820% over the last month—strongly negative near-term signal.
No supportive news flow: No recent news/catalysts reported in the past week to reverse momentum.
Profitability and margins deteriorating: Losses and EPS worsened YoY and gross margin declined, which can pressure biotech sentiment outside of catalyst windows.
Quant-style near-term odds: Pattern-based projection suggests downside bias over the next week and month.
Latest quarter: 2025/Q3. Revenue increased to $116.10M (+13.52% YoY), but profitability weakened: net income fell to -$35.96M (more negative by ~13.70% YoY), EPS to -$0.03 (-25% YoY). Gross margin declined to 60.13% (-5.90% YoY). Net takeaway: growth is improving on the top line, but operating leverage/margins are moving the wrong way in the latest quarter.
Recent changes: (1) 2026-01-07 UBS initiated coverage with a Buy rating and a $35 price target (constructive, high-upside framing). (2) 2025-11-03 Goldman Sachs removed ZLAB from its APAC Conviction List (negative relative signal). Wall Street pros: large implied upside from UBS, improving biotech backdrop narrative. Wall Street cons: removal from a conviction list suggests reduced confidence/priority; absent fresh catalysts, the market is currently rewarding trend and execution, where ZLAB’s recent margin/EPS direction is a headwind. Influential/political trading: No recent congress trading data available; hedge fund activity noted as neutral.
